The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 27, 2015

Filed:

Oct. 13, 2011
Applicants:

Mark G. Saulnier, Higganum, CT (US);

Dolatrai M. Vyas, Madison, CT (US);

David R. Langley, Meriden, CT (US);

David B. Frennesson, Naugatuck, CT (US);

Inventors:

Mark G. Saulnier, Higganum, CT (US);

Dolatrai M. Vyas, Madison, CT (US);

David R. Langley, Meriden, CT (US);

David B. Frennesson, Naugatuck, CT (US);

Assignee:

Bristol-Myers Squibb Company, Princeton, NJ (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 7/64 (2006.01); C07K 5/12 (2006.01); C07D 277/42 (2006.01); C07D 417/04 (2006.01); C07K 1/113 (2006.01);
U.S. Cl.
CPC ...
C07K 7/64 (2013.01); C07D 277/42 (2013.01); C07D 417/04 (2013.01); C07K 1/1136 (2013.01); C07K 5/123 (2013.01); C07K 5/126 (2013.01);
Abstract

The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.


Find Patent Forward Citations

Loading…